Med24
overweight-obesity 14. 10. 2026 • 2 min read • Obesity pillars

Efficacy and safety of orforglipron in adults with body mass index of 27 to less than 30 kg/m 2 and adiposity-related complications: A post hoc analysis of the ATTAIN-1 trial

Background Orforglipron, an oral small-molecule glucagon-like peptide-1 receptor agonist, improved body weight and cardiometabolic parameters in the phase 3 ATTAIN-1 trial, but its efficacy and safety in adults with body mass index (BMI) of ≥27 to 2 and adiposity-related complications have not been characterized....

Addressing Post-Intensive Care Syndrome Among Survivors of COVID (APICS-COVID)

A post hoc analysis of the ATTAIN-1 trial examined the efficacy and safety of orforglipron in adults with a body mass index of 27 to less than 30 kg/m² and at least one adiposity-related complication. The trial, identified by NCT05869903, was a phase 3, randomized, double-blind, placebo-controlled study.

Key Clinical Findings

Participants were randomized 3:3:3:4 to once-daily orforglipron at doses of 5.5, 9, or 17.2 mg, or placebo, for 72 weeks. The analysis included 260 participants, divided into four groups receiving orforglipron (5.5 mg, 64; 9 mg, 64; 17.2 mg, 62) and a placebo group (78). The primary endpoints assessed changes in body weight, BMI, waist circumference, lipids, patient-reported outcomes, and safety measures from baseline to Week 72.

Sponsored content

Efficacy Results

At Week 72, orforglipron demonstrated a greater mean percent body weight reduction (17.2 mg: -13.5%) compared to placebo (-0.3%) regarding the nominal p value. This analysis focused on individuals with overweight and at least one adiposity-related complication, a group considered to be at substantial cardiometabolic risk. The results indicated improvements in anthropometric and cardiometabolic parameters with orforglipron treatment. The safety profile of orforglipron was broadly consistent with the overall findings of the ATTAIN-1 trial and involved the administration of

Original Scientific Source
Obesity pillars
View Original Source
Medical Disclaimer All calculations, recommendations, and interpretations provided by this tool are for informational and educational purposes only. They do not substitute professional medical advice, diagnosis, or treatment. Always consult your physician regarding any health concerns.

Recommended Medical News

All news →
Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study
overweight-obesity

Genetic axes of hand and shoulder soft-tissue disease and their divergent responses to adiposity and incretin therapy: a cross-biobank genomic and randomised trial study

Summary Background Hand and shoulder soft-tissue disorders cluster in people with obesity and diabetes, now widely treated with incretin receptor agonists. Whether these disorders share genetic causes, and whether pharmacological weight loss relieves or provokes them, is unknown. Methods We analysed genome-wide data...

28. 10. 2026 Read article →
The interpretation of body-composition metrics in obesity
overweight-obesity

The interpretation of body-composition metrics in obesity

Modern obesity care is increasingly therapeutic, longitudinal, and outcome-oriented, yet clinical assessment often remains centered on total body weight and BMI. Although BMI remains useful for screening and population-level risk stratification, it cannot characterize the biological heterogeneity of obesity or the...

26. 10. 2026 Read article →
Advertisement